What do we gain from the sixth coronary heart disease drug?: Not much: guidelines must consider cost effectiveness
AUTOR(ES)
Warburton, Rebecca N
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=286232Documentos Relacionados
- Coronary heart disease prevention: insights from modelling incremental cost effectiveness
- Coronary heart disease prevention: insights from modelling incremental cost effectiveness
- Prevention of coronary heart disease: Incremental cost effectiveness raises issues
- How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis
- Coexisting Coronary and Carotid Artery Disease: What We Did, What Happened